Biological Therapies for Atrial Fibrillation: Ready for Prime Time?

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 1, 2016, Pages 19-25

  Donahue, J Kevin ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Atrial fibrillation; atrioventricular node; cell therapy; conduction; gene therapy; repolarization

Indexed keywords

VIRUS VECTOR; ANTIARRHYTHMIC AGENT;

ATRIAL FIBRILLATION; ATRIAL GENE DELIVERY; ATRIAL THROMBORESISTANCE; ATRIOVENTRICULAR NODAL GENE DELIVERY; BIOLOGICAL THERAPY; CELL THERAPY; DNA VECTOR; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HEART ATRIOVENTRICULAR NODE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHYTHM CONTROL THERAPY; ANIMAL; GENETICS; PROCEDURES; TIME FACTOR; TRENDS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL THERAPY; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; TIME FACTORS;

EID: 84954284908     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000293     Document Type: Review

References (54)

1. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112:1142-1147.
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370-2375.
3. Schnabel RB, Wilde S, Wild PS, et al. Atrial fibrillation: its prevalence and risk factor profile in the German general population. Dtsch Arztebl Int. 2012;109:293-299.
4. Heart and Stroke Foundation of Canada. Statistics. 2014. Available at: http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm. Accessed Dec 15, 2014.
5. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American heart association. Circulation. 2014;129:e28-e292.
6. PricewaterhouseCoopers. The economic costs of atrial fibrillation in Australia. June 2010. Available at: http://www.strokefoundation.com.au/index2.phpoption=com-docman&task=doc-view&gid=318&Itemid=39 Accessed Dec 15, 2014.
7. Reynolds M, Essebag V, Zimetbaum P, et al. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007;18:628-633.
8. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837-847.
9. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42: 20-29.
10. Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329-345.
11. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
12. Cappato R, Calkins H, Chen SA, et al. Updated Worldwide Survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:32-38.
13. Gaita F, Caponi D, Pianelli M, et al. Radiofrequency catheter ablation of atrial fibrillation: a cause of silent thromboembolism Magnetic resonance imaging assessment of cerebral thromboembolism in patients undergoing ablation of atrial fibrillation. Circulation. 2010;122:1667-1673.
14. Blitzer M, Costeas C, Kassotis J, et al. Rhythm management in atrial fibrillation-with a primary emphasis on pharmacological therapy: Part 1. Pacing Clin Electrophysiol. 1998;21:590-602.
15. Lin H, Parmacek M, Morle G, et al. Expression of recombinant genes in the myocardium in vivo after direct injection of DNA. Circulation. 1990; 82:2217-2221.
16. Buttrick P, Kass A, Kitsis R, et al. Behavior of genes directly injected into the rate heart in vivo. Circ Res. 1992;70:193-198.
17. Guzman RJ, Lemarchand P, Crystal R, et al. Efficient gene transfer into myocardium by direct injection of adenovirus vectors. Circ Res. 1993;73: 1202-1207.
18. Shenk T. Adenoviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott-Raven; 1996:2111-2148.
19. Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 2009;16:629-634.
20. Kukula K, Chojnowska L, Dabrowski M, et al. Intramyocardial plasmidencoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J. 2011;161:581-589.
21. Gupta R, Tongers J, Losordo DW. Human studies of angiogenic gene therapy. Circ Res. 2009;105:724-736.
22. Kotin RM. Prospects for the use of adeno-associated virus as a vector for human gene therapy. Hum Gene Ther. 1994;5:793-801.
23. Ferrari F, Samulski T, Shenk T, et al. Second-strand synthesis is a ratelimiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol. 1996;70:3227-3234.
24. Hauck B, Zhao W, High K, et al. Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adenoassociated virus transduction. J Virol. 2004;78:13678-13686.
25. Jaski BE, Jessup ML, Mancini DM, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. J Card Fail. 2009;15:171-181.
26. Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+ATPase in patients with advanced heart failure. Circulation. 2011; 124:304-313.
27. Wiklund F. Celladon reports negative results for CUPID2 trial of Mydicar( R) in advanced heart failuer. 2015. Available at: http://ir.celladon.net/releasedetail.cfmReleaseID=908592. Accessed May 15, 2015.
28. Donahue JK, Heldman AW, Fraser H, et al. Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med. 2000;6:1395-1398.
29. Kikuchi K, McDonald AD, Sasano T, et al. Targeted modification of atrial electrophysiology by homogeneous transmural atrial gene transfer. Circulation. 2005;111:264-270.
30. Donahue JK, Kikkawa K, Johns DC, et al. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA. 1997;94:4664-4668.
31. Donahue JK, Kikkawa K, Thomas AD, et al. Acceleration of widespread adenoviral gene transfer to intact rabbit hearts by coronary perfusion with low calcium and serotonin. Gene Ther. 1998;5:630-634.
32. Nagata K, Marban E, Lawrence JH, et al. Phosphodiesterase inhibitormediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol. 2001;33:575-580.
33. Sasano T, Kikuchi K, Feng N, et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol. 2007;42:954-961.
34. Roth D, Lai N, Gao M, et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther. 2004;15:989-994.
35. Karakikes I, Hadri L, Rapti K, et al. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol Ther. 2012;20:565-571.
36. Kass-Eisler A, Falck-Pedersen E, Alvira M, et al. Quantitative determination of adenovirus-mediated gene delivery to rat cardiac myocytes in vitro and in vivo. Proc Natl Acad Sci USA. 1993;90: 11498-11502.
37. French B, Mazur W, Geske R, et al. Direct in vivo gene transfer into porcine myocardium using replication-deficient adenoviral vectors. Circulation. 1994;90:2414-2424.
38. Bikou O, Thomas D, Trappe K, et al. Connexin 43 gene therapy prevents persistent atrial fibrillation in a porcine model. Cardiovasc Res. 2011;92: 218-225.
39. Trappe K, Thomas D, Bikou O, et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study. Eur Heart J. 2013;34:147-157.
40. Soucek R, Thomas D, Kelemen K, et al. Genetic suppression of atrial fibrillation using a dominant-negative ether-a-go-go-related gene mutant. Heart Rhythm. 2012;9:265-272.
41. Aistrup GL, Cokic I, Ng J, et al. Targeted nonviral gene-based inhibition of Galpha(i/o)-mediated vagal signaling in the posterior left atrium decreases vagal-induced atrial fibrillation. Heart Rhythm. 2011;8:1722-1729.
42. Hargrave B, Downey H, Strange R Jr, et al. Electroporation-mediated gene transfer directly to the swine heart. Gene Ther. 2013;20: 151-157.
43. Bauer A, McDonald AD, Donahue JK. Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation. Circulation. 2004;110:3115-3120.
44. Lugenbiel P, Thomas D, Kelemen K, et al. Genetic suppression of Galphas protein provides rate control in atrial fibrillation. Basic Res Cardiol. 2012;107:265.
45. Bunch T, Mahapatra S, Bruce G, et al. Impact of transforming growth factor-beta1 on atrioventricular node conduction modificaiton by injected autologous fibroblasts in the canine heart. Circulation. 2006;113:2485-2494.
46. Nattel S. Therapeutic implications of atrial fibrillation mechanisms: can mechanistic insights be used to improve AF management Cardiovasc Res. 2002;54:347-360.
47. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res. 2002;54:230-246.
48. Ausma J, Wijffels M, Thone F, et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation. 1997; 96:3157-3163.
49. Wijffels M, Kirchhof C, Dorland R, et al. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-1968.
50. Amit G, Kikuchi K, Greener ID, et al. Selective molecular potassium channel blockade prevents atrial fibrillation. Circulation. 2010;121: 2263-2270.
51. Perlstein I, Burton D, Ryan K, et al. Posttranslational control of a cardiac ion channel transgene in vivo: clarithromyhcin-hMIRP1-Q9E interactions. Hum Gene Ther. 2005;16:906-910.
52. Igarashi T, Finet JE, Takeuchi A, et al. Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation. 2012; 125:216-225.
53. Zhou Z, Gong Q, Ye B, et al. Properties of HERG channels stably expressed in HEK293 cells studied at physiological temperature. Biophys J. 1998;74:230-241.
54. Kapur NK, Deming CB, Kapur S, et al. Hemodynamic modulation of endocardial thromboresistance. Circulation. 2007;115:67-75